Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
BACKGROUND
The present study aimed at evaluation of changes in estimated glomerular filtration rate (eGFR) among chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) Stages 3-5 who were treated with 12 weeks of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin.


METHODS
Changes in renal functions were compared across follow up time points (baseline, SVR4, and SVR8). Data on on-treatment adverse events (AEs), serious AEs, laboratory abnormalities, treatment discontinuation were collected.


RESULTS
171 patients were included (females 35%, mean age 53 years). 29 patients had liver cirrhosis. The most common etiologies of CKD were diabetes and/or hypertension (n = 67). All included patient reached the end of treatment (EOT) with no treatment discontinuations. The overall EOT response was 100%. 122/122 (100%) patients who reached 4 weeks post-treatment have achieved SVR4, and 80/80 (100%) have achieved SVR12. No reported SAEs. Ribavirin therapy was interrupted in 25% (43/171) of patients due to anemia; 16 patients required blood transfusions. The median eGFR improved from 33.5 (15) mL/min/1.73 m2 at baseline to 35 (36) mL/min/1.73 m2 at SVR8 (p = 0.0003).


CONCLUSIONS
The use of ombitasvir, paritaprevir, and ritonavir for treatment of HCV-infected patients with advanced renal disease was safe and effective, moreover, it was associated with significantly improved eGFR.
['Said|Mohamed|M|', 'Omar|Heba|H|http://orcid.org/0000-0002-9707-1141', 'Soliman|Zeinab|Z|', 'Saad|Yasmin|Y|', 'Dabes|Hosam|H|', 'Hamed|Sozan|S|', 'ElSaeed|Kadri|K|', 'ElShazly|Yehia|Y|', 'ElSerafy|Magdi|M|']
D000328:Adult D000368:Aged D000813:Anilides D000998:Antiviral Agents D002219:Carbamates D003521:Cyclopropanes D004359:Drug Therapy, Combination D004534:Egypt D005260:Female D005838:Genotype D005919:Glomerular Filtration Rate D016174:Hepacivirus D019698:Hepatitis C, Chronic D006801:Humans D007668:Kidney D047029:Lactams, Macrocyclic D047028:Macrocyclic Compounds D008297:Male D008875:Middle Aged D011392:Proline D011446:Prospective Studies D020127:Recovery of Function D006435:Renal Dialysis D051436:Renal Insufficiency, Chronic D012254:Ribavirin D013449:Sulfonamides D000072230:Sustained Virologic Response D013997:Time Factors D016896:Treatment Outcome D014633:Valine D019562:Viral Load D055815:Young Adult
ritonavir-boosted paritaprevir ombitasvir eGFR HCV chronic kidney disease genotype 4 real-world